Cosmetic Regulatory Compliance & Product Quality Surveillance: Drug Administration of Vietnam (DAV) Issues Nationwide Recall for Feminine Wash, Shampoos, and Body Washes Over Microbial Limit Exceedances and Unapproved Formulation Discrepancies

Key Development

In early September 2026, the Drug Administration of Vietnam (DAV) under the Ministry of Health issued nationwide distribution suspensions, mandatory product recalls, and destruction orders targeting multiple commercial batches of personal care and cosmetic hygiene products (including feminine intimate wash, body washes, shampoos, conditioners, and hand soaps) following confirmed quality failures and regulatory non-compliance:

Product Batches & Specific Regulatory Breaches:

• Feminine Intimate Wash Failing Microbiological Quality Standards:

  • Product Name: Victory Herbal Feminine Hygiene Solution (Dung dịch vệ sinh phụ nữ Thảo dược Victory, 300 mL bottle).

  • Regulatory Batch Identifiers: Cosmetic Notification Receipt: 06/26/CBMP-NA; Batch Number: 010426; Manufacturing Date: April 15, 2026; Shelf-life: 36 months.

  • Responsible Entity & Manufacturer: Chien Thang Pharmaceutical Co., Ltd. (Công ty TNHH Dược Chiến Thắng, located in Nghe An province).

  • Regulatory Breach: Laboratory test samples failed quality standards regarding permissible microbiological limit thresholds established under the ASEAN Cosmetic Directive (ACD).

• Multiple Formulations Deviating from Approved Cosmetic Filings:

  • Manufacturing Contractor: Bao Loi Cosmetics Co., Ltd. (Công ty TNHH Mỹ phẩm Bảo Lợi, Hai Phong City).

  • Regulatory Breach: Commercial products distributed across retail markets contained chemical formulation compositions inconsistent with approved notification dossiers filed with regulatory authorities.

  • Affected Product Lines:

    1. CURIA Shampoo (Notification Receipt: 200/25/CBMPHD, marketed by Bao Loi Cosmetics Co., Ltd.).

    2. Four distinct products under the VLIACARE brand franchise (encompassing body wash, shampoo, hair conditioner, and liquid hand soap), distributed commercially by Nhat Linh Glow Beauty Co., Ltd. (Hanoi).

• Enforcement & Mandatory Corrective Mandates: The DAV ordered all wholesale distributors, retail pharmacies, retail chains, and beauty salons nationwide to immediately cease commercial sales and usage, quarantine existing stocks, and process returns to suppliers. Concurrently, municipal Departments of Health (Hanoi, Hai Phong, Nghe An) were instructed to supervise product recalls and physical destruction, while conducting comprehensive cGMP audits across manufacturing sites.

Why It Matters

• Gynecological Infection Hazards from Contaminated Intimate Hygiene Formulations: The delicate vaginal mucosal microenvironment depends on mucosal epithelial integrity and protective symbiotic flora (Lactobacillus species). Administering feminine hygiene washes contaminated with elevated bacterial or fungal bioburdens risks inducing vulvovaginitis, contact mucositis, and ascending pelvic infections, posing tangible risks to female reproductive health.

• Toxicological and Dermatological Hazards from Unapproved Formulation Variations: Modifying formulation matrices without regulatory clearance (such as altering active surfactant systems, cutting active botanical extracts, or altering preservative concentrations like parabens or formaldehyde releasers) exposes end-users to contact dermatitis, epidermal barrier breakdown, and cumulative toxic chemical exposures lacking safety assessments.

• Strengthening Post-Market Cosmetic Surveillance: Under the ASEAN Cosmetic Directive harmonized framework, cosmetic products access markets via notification mechanisms accompanied by post-market surveillance. Sequential enforcement actions—spanning Layer Clean antibacterial foaming soap, Kencare cosmetics, and now Chien Thang Pharmaceutical and Bao Loi—demonstrate heightened regulatory post-market sampling and laboratory oversight by Vietnamese authorities.

Healthcare Insight Analysis

From the perspective of Healthcare Insight, the sweeping product recalls executed in September 2026 demonstrate Post-Market Cosmetic Surveillance & Formulation Integrity Enforcement.

The administrative actions highlight three critical regulatory and manufacturing challenges:

1. Sanitation and Quality Control Breakdowns in Regional Contract Manufacturing: The microbial contamination identified in Chien Thang Pharmaceutical’s feminine wash reflects common systemic vulnerabilities in regional manufacturing: unvalidated purified water treatment loops, unclassified packaging environments, or preservative system destabilization.

2. Economic Adulteration and Dossier Divergence: Formulation discrepancies identified across Bao Loi Cosmetics and Nhat Linh Glow Beauty reflect structural vulnerabilities within private-label OEM/ODM cosmetic supply chains. Submitting compliant, high-grade formulation dossiers for initial administrative notification while substituting lower-cost raw materials during commercial scale-up constitutes economic adulteration.

3. Shared Legal Accountability Across the Distribution Chain: The enforcement actions targeting the VLIACARE franchise clarify that marketing and distribution brand-holders cannot outsource regulatory liability to third-party contract packagers. Both the commercial registrant and the contracted manufacturing facility face regulatory penalties and recall expenses.

Market Implications

1. Channel Screening Across Pharmacy and Retail Chains: Modern pharmacy retail chains (Long Chau, Pharmacity, An Khang) and digital e-commerce marketplaces (Shopee, TikTok Shop, Lazada) will immediately delist non-compliant SKUs and implement stricter certificates of analysis (COA) verification protocols for domestic personal care products.

2. Targeted Inspections by Municipal Health Authorities: Health inspection departments in Nghe An, Hai Phong, and Hanoi will conduct unannounced audits of batch production records, raw material qualification files, and stability testing documentation at involved production facilities.

3. Market Consolidation Favoring Certified cGMP-ASEAN Manufacturers: Increasing regulatory enforcement raises the cost of non-compliance, directing commercial OEM contract manufacturing volumes toward professional facilities operating under verified cGMP-ASEAN or ISO 22716 certifications.

Product Regulatory Summary Matrix: DAV Cosmetic Suspension & Recall Orders (September 2026)

Source: https://tuoitre.vn/thu-hoi-toan-quoc-loat-dung-dich-ve-sinh-phu-nu-sua-tam-dau-goi-vi-pham-100260907211648962.htm